Statins inhibit 3-hydroxy-3-methylglutaryl CoA reductase to reduce cardiovascular risk, but may induce neuropsychiatric adverse effects. Sleep disturbances, especially insomnia and vivid dreams, are frequently reported, particularly with lipophilic statins that cross the blood–brain barrier (BBB). However, randomized trials often show minimal objective effects, highlighting the need for integrated evidence. This narrative review synthesized data from human clinical trials, pharmacovigilance databases, animal studies, and molecular investigations to clarify the relationship between statin lipophilicity and sleep outcomes. The evidence remains mixed. Objective polysomnography trials generally show minimal adverse effects or slight improvements in sleep continuity, particularly with the use of hydrophilic statins. In contrast, real-world data and case reports indicate higher rates of insomnia and nightmares with lipophilic agents, particularly simvastatin, likely reflecting pharmacokinetic differences and possible nocebo effects. Lipophilic statins may influence brain cholesterol metabolism and neurotransmission, contributing to subjective sleep disturbances, whereas hydrophilic statins appear to be sleep-neutral. BBB penetration is a key determinant. Future head-to-head trials and individualized prescriptions may optimize the benefit-to-risk balance.
Salari et al. (Thu,) studied this question.